| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Franjo Grotenherme. Pharmacokinetics and pharmacodynamics of cannabinoids. Clinical pharmacokinetics. vol 42. issue 4. 2003-06-11. PMID:12648025. |
natural cannabis products and single cannabinoids are usually inhaled or taken orally; the rectal route, sublingual administration, transdermal delivery, eye drops and aerosols have only been used in a few studies and are of little relevance in practice today. |
2003-06-11 |
2023-08-12 |
Not clear |
| Maurizio Bifulco, Vincenzo Di Marz. [The endocannabinoid system as a target for the development of new drugs for cancer therapy]. Recenti progressi in medicina. vol 94. issue 5. 2003-06-09. PMID:12723496. |
studies on the main bioactive components of cannabis sativa, the cannabinoids, and particularly delta 9-tetrahydrocannabinol (thc), led to the discovery of a new endogenous signalling system that controls several physiological and pathological conditions: the endocannabinoid system. |
2003-06-09 |
2023-08-12 |
Not clear |
| Roger G Pertwee, Ruth A Ross, Susan J Craib, Adèle Thoma. (-)-Cannabidiol antagonizes cannabinoid receptor agonists and noradrenaline in the mouse vas deferens. European journal of pharmacology. vol 456. issue 1-3. 2003-05-19. PMID:12450575. |
we have found that cannabidiol can also interact with cannabinoid cb(1) receptor agonists in the mouse vas deferens, a tissue in which prejunctional cannabinoid cb(1) receptors mediate inhibition of electrically evoked contractions by suppressing noradrenaline and/or atp release. |
2003-05-19 |
2023-08-12 |
mouse |
| Roger G Pertwee, Ruth A Ross, Susan J Craib, Adèle Thoma. (-)-Cannabidiol antagonizes cannabinoid receptor agonists and noradrenaline in the mouse vas deferens. European journal of pharmacology. vol 456. issue 1-3. 2003-05-19. PMID:12450575. |
we conclude that cannabidiol antagonizes r-(+)-win55212 and cp55940 by acting at prejunctional sites that are unlikely to be cannabinoid cb(1) or cb(2) receptors. |
2003-05-19 |
2023-08-12 |
mouse |
| László Offertáler, Fong-Ming Mo, Sándor Bátkai, Jie Liu, Malcolm Begg, Raj K Razdan, Billy R Martin, Richard D Bukoski, George Kuno. Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor. Molecular pharmacology. vol 63. issue 3. 2003-05-12. PMID:12606780. |
the cannabinoid analog abnormal cannabidiol [abn-cbd; (-)-4-(3-3,4-trans-p-menthadien-[1,8]-yl)-olivetol] does not bind to cb(1) or cb(2) receptors, yet it acts as a full agonist in relaxing rat isolated mesenteric artery segments. |
2003-05-12 |
2023-08-12 |
mouse |
| Albert D Fraser, David Wort. Monitoring urinary excretion of cannabinoids by fluorescence-polarization immunoassay: a cannabinoid-to-creatinine ratio study. Therapeutic drug monitoring. vol 24. issue 6. 2003-05-07. PMID:12451292. |
huestis reported that serial monitoring of the major urinary cannabinoid metabolite (delta9-thc-cooh)-to-creatinine ratios in paired urine specimens (collected at least 24 hours apart) could differentiate new marijuana or hashish use from residual cannabinoid metabolite excretion in urine after previous drug use. |
2003-05-07 |
2023-08-12 |
human |
| Albert D Fraser, David Wort. Monitoring urinary excretion of cannabinoids by fluorescence-polarization immunoassay: a cannabinoid-to-creatinine ratio study. Therapeutic drug monitoring. vol 24. issue 6. 2003-05-07. PMID:12451292. |
the objective of this study was to determine whether a semiquantitative cannabinoids immunoassay (corrected for creatinine concentration) could differentiate new marijuana use from residual cannabinoid excretion in chronic users of marijuana or hashish compared with gc-ms. |
2003-05-07 |
2023-08-12 |
human |
| Albert D Fraser, David Wort. Monitoring urinary excretion of cannabinoids by fluorescence-polarization immunoassay: a cannabinoid-to-creatinine ratio study. Therapeutic drug monitoring. vol 24. issue 6. 2003-05-07. PMID:12451292. |
the authors conclude that fpia cannabinoid analysis should be further evaluated as an alternative to gc-ms quantitation to help distinguish new marijuana use from residual marijuana metabolite excretion in clinical drug treatment programs. |
2003-05-07 |
2023-08-12 |
human |
| Angelika Richter, Wolfgang Lösche. Effects of pharmacological manipulations of cannabinoid receptors on severity of dystonia in a genetic model of paroxysmal dyskinesia. European journal of pharmacology. vol 454. issue 2-3. 2003-05-06. PMID:12421641. |
was confirmed, cannabidiol (which has low affinity to cannabinoid receptors) tended to delay the progression of dystonia only at a high dose (150 mg/kg i.p.). |
2003-05-06 |
2023-08-12 |
Not clear |
| Paul Lecha. [Does cannabis have a therapeutic value?]. Bulletin de l'Academie nationale de medecine. vol 186. issue 2. 2003-04-29. PMID:12145840. |
researches on endogenous cannabinoids as well as on cannabinoids receptors agonists and antagonists may lead to discover new useful drugs devoid of the central nervous system unwanted effects of cannabis. |
2003-04-29 |
2023-08-12 |
Not clear |
| Carl L Hart, Amie S Ward, Margaret Haney, Sandra D Comer, Richard W Foltin, Marian W Fischma. Comparison of smoked marijuana and oral Delta(9)-tetrahydrocannabinol in humans. Psychopharmacology. vol 164. issue 4. 2003-04-23. PMID:12457271. |
although smoked marijuana contains at least 60 cannabinoids, delta(9)-tetrahydrocannabinol (delta(9)-thc) is presumed to be the cannabinoid primarily responsible for many marijuana-related effects, including increased food intake and subjective effects. |
2003-04-23 |
2023-08-12 |
Not clear |
| D Cota, G Marsicano, B Lutz, V Vicennati, G K Stalla, R Pasquali, U Pagott. Endogenous cannabinoid system as a modulator of food intake. International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity. vol 27. issue 3. 2003-04-17. PMID:12629555. |
despite the public concern related to the abuse of marijuana and its derivatives, scientific studies have pointed to the therapeutic potentials of cannabinoid compounds and have highlighted their ability to stimulate appetite, especially for sweet and palatable food. |
2003-04-17 |
2023-08-12 |
human |
| D Cota, G Marsicano, B Lutz, V Vicennati, G K Stalla, R Pasquali, U Pagott. Endogenous cannabinoid system as a modulator of food intake. International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity. vol 27. issue 3. 2003-04-17. PMID:12629555. |
later, the discovery of specific receptors and their endogenous ligands (endocannabinoids) suggested the existence of an endogenous cannabinoid system, providing a physiological basis for biological effects induced by marijuana and other cannabinoids. |
2003-04-17 |
2023-08-12 |
human |
| Roger G Pertwe. Cannabinoids and multiple sclerosis. Pharmacology & therapeutics. vol 95. issue 2. 2003-04-03. PMID:12182963. |
there is a growing amount of evidence to suggest that cannabis and individual cannabinoids may be effective in suppressing certain symptoms of multiple sclerosis and spinal cord injury, including spasticity and pain. |
2003-04-03 |
2023-08-12 |
mouse |
| Roger G Pertwe. Cannabinoids and multiple sclerosis. Pharmacology & therapeutics. vol 95. issue 2. 2003-04-03. PMID:12182963. |
future research should also be directed at obtaining more conclusive evidence about the efficacy of cannabis or individual cannabinoids against the signs and symptoms of these disorders, at devising better modes of administration for cannabinoids and at exploring strategies that maximize separation between the sought-after therapeutic effects and the unwanted effects of these drugs. |
2003-04-03 |
2023-08-12 |
mouse |
| Albert D Fraser, Lawrence Coffin, David Wort. Drug and chemical metabolites in clinical toxicology investigations: the importance of ethylene glycol, methanol and cannabinoid metabolite analyses. Clinical biochemistry. vol 35. issue 7. 2003-04-02. PMID:12493577. |
serial monitoring of the major urinary cannabinoid metabolite (delta(9)-thc-cooh) to creatinine ratios in paired urine specimens (collected at least 24 h apart) could differentiate new marijuana or hashish use from residual cannabinoid metabolite excretion in urine after drug use according to huestis. |
2003-04-02 |
2023-08-12 |
human |
| Albert D Fraser, Lawrence Coffin, David Wort. Drug and chemical metabolites in clinical toxicology investigations: the importance of ethylene glycol, methanol and cannabinoid metabolite analyses. Clinical biochemistry. vol 35. issue 7. 2003-04-02. PMID:12493577. |
the second objective is to demonstrate that creatinine corrected urine specimens positive for cannabinoids may help differentiate new marijuana use from the excretion of residual delta(9) -thc-cooh in chronic users of marijuana or hashish. |
2003-04-02 |
2023-08-12 |
human |
| Cristina Blázquez, M Llanos Casanova, Anna Planas, Teresa Gómez Del Pulgar, Concepción Villanueva, María J Fernández-Aceñero, Julián Aragonés, John W Huffman, José L Jorcano, Manuel Guzmá. Inhibition of tumor angiogenesis by cannabinoids. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. vol 17. issue 3. 2003-04-01. PMID:12514108. |
cannabinoids, the active components of marijuana and their derivatives, induce tumor regression in rodents (8). |
2003-04-01 |
2023-08-12 |
mouse |
| Camila Scorticati, Claudia Mohn, Andrea De Laurentiis, Paula Vissio, Javier Fernández Solari, Adriana Seilicovich, Samuel M McCann, Valeria Rettor. The effect of anandamide on prolactin secretion is modulated by estrogen. Proceedings of the National Academy of Sciences of the United States of America. vol 100. issue 4. 2003-04-01. PMID:12578974. |
recent research has revealed that endogenous cannabinoid receptors (cb1 and cb2) react with the active ingredient of marijuana, delta(9)-tetrahydrocannabinol. |
2003-04-01 |
2023-08-12 |
rat |
| J Ludovic Croxfor. Therapeutic potential of cannabinoids in CNS disease. CNS drugs. vol 17. issue 3. 2003-03-31. PMID:12617697. |
the major psychoactive constituent of cannabis sativa, delta(9)-tetrahydrocannabinol (delta(9)-thc), and endogenous cannabinoid ligands, such as anandamide, signal through g-protein-coupled cannabinoid receptors localised to regions of the brain associated with important neurological processes. |
2003-03-31 |
2023-08-12 |
Not clear |